{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:07:00Z","timestamp":1789556820557,"version":"build-2803163510"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"unspecified","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Applied Therapeutics"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,7,22]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Racial and ethnic differences in diabetic cardiomyopathy (DbCM) exist, with black and Hispanic participants showing poorer health status. It remains unclear whether these differences affect the natural progression of the disease. We aimed to evaluate disease progression in individuals with DbCM, as well as racial differences in the response to AT-001.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 625 participants with DbCM were randomised to either placebo or AT-001 and followed for 15 months. The primary outcome was change in peak oxygen uptake (peak VO\n                      <jats:sub>2<\/jats:sub>\n                      ) and secondary outcomes included Kansas City Cardiomyopathy Questionnaire (KCCQ) and Physical Activity Scale for the Elderly scores. Analyses were stratified by race and ethnicity (black, Hispanic, white).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Black and Hispanic participants who received placebo experienced greater declines in peak VO\n                      <jats:sub>2<\/jats:sub>\n                      (\u22120.74 and \u22121.67\u2009mL\/kg\/min, respectively) compared with white participants (\u22120.23\u2009mL\/kg\/min, p=0.005). AT-001 demonstrated a non-statistically significant trend towards slower declines in peak VO\n                      <jats:sub>2<\/jats:sub>\n                      in black and Hispanic participants (\u22120.31 and \u22120.62\u2009mL\/kg\/min, p=0.29, respectively). Black participants who received placebo had the largest declines in most KCCQ scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Black and Hispanic participants with DbCM experienced faster disease progression, with black participants showing the most pronounced functional and quality of life declines. The effect of AT-001 on peak VO\n                      <jats:sub>2<\/jats:sub>\n                      changes was not statistically significant with similar effects between racial and ethnic groups (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04083339\">NCT04083339<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04083339\">NCT04083339<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2026-004312","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:20:20Z","timestamp":1785496820000},"page":"e004312","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04083339","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04083339","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04083339","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-2249","authenticated-orcid":false,"given":"Jose L.","family":"Batista","sequence":"first","affiliation":[{"name":"Section of Clinical Cardiac Electrophysiology, University of Michigan Samuel and Jean Frankel Cardiovascular Center, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Massachusetts General Hospital, Baim Institute for Clinical Research, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Medical Center, The University of Mississippi Medical Center, Jackson, Mississippi, USA"},{"name":"Baylor Scott and White Research Institute, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2724-4086","authenticated-orcid":false,"given":"Justin A","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Cardiology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Cardiology, National Heart Centre Singapore and Duke-National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H","family":"Marwick","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W H Wilson","family":"Tang","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[{"name":"Applied Therapeutics, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Urbinati","sequence":"additional","affiliation":[{"name":"Applied Therapeutics, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Clinical investigation center, Centre Hospitalier Universitaire de Nancy, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2038-7786","authenticated-orcid":false,"given":"Onyedika","family":"Ilonze","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Massachusetts General Hospital, Baim Institute for Clinical Research, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026091603501401000_13.2.e004312.1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(74)90089-7"},{"key":"2026091603501401000_13.2.e004312.2","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s11886-023-01994-4","article-title":"Achieving Health Equity in the Care of Patients with Heart Failure","volume":"25","author":"Lopez","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"2026091603501401000_13.2.e004312.3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091603501401000_13.2.e004312.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.05.019"},{"key":"2026091603501401000_13.2.e004312.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.019"},{"key":"2026091603501401000_13.2.e004312.6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.hfc.2019.02.003","article-title":"Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications","volume":"15","author":"Paolillo","year":"2019","journal-title":"Heart Fail Clin"},{"key":"2026091603501401000_13.2.e004312.7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2026091603501401000_13.2.e004312.8","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001063"},{"key":"2026091603501401000_13.2.e004312.9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jacc.2024.03.380","article-title":"Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy","volume":"84","author":"Januzzi","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026091603501401000_13.2.e004312.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311586"},{"key":"2026091603501401000_13.2.e004312.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-012-9313-3"},{"key":"2026091603501401000_13.2.e004312.12","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1615"},{"key":"2026091603501401000_13.2.e004312.13","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2009.2502"},{"key":"2026091603501401000_13.2.e004312.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.213447"},{"key":"2026091603501401000_13.2.e004312.15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ahj.2022.11.003","article-title":"Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy","volume":"256","author":"Januzzi","year":"2023","journal-title":"Am Heart J"},{"key":"2026091603501401000_13.2.e004312.16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacc.2024.04.053","article-title":"Racial Differences in Diabetic Cardiomyopathy","volume":"84","author":"Batista","year":"2024","journal-title":"JACC"},{"key":"2026091603501401000_13.2.e004312.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.115.001958"},{"key":"2026091603501401000_13.2.e004312.18","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90053-4"},{"key":"2026091603501401000_13.2.e004312.19","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jcmg.2022.03.007","article-title":"Improving the Characterization of Stage A and B Heart Failure by Adding Global Longitudinal Strain","volume":"15","author":"Haji","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026091603501401000_13.2.e004312.20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ejhf.632","article-title":"Global longitudinal strain: the best biomarker for predicting prognosis in heart failure?","volume":"18","author":"Haugaa","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026091603501401000_13.2.e004312.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.07.016"},{"key":"2026091603501401000_13.2.e004312.22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1249\/MSS.0b013e318271689e","article-title":"Association of physical activity, fitness, and race: NHANES 1999\u20132004","volume":"45","author":"Ceaser","year":"2013","journal-title":"Med Sci Sports Exerc"},{"key":"2026091603501401000_13.2.e004312.23","doi-asserted-by":"publisher","DOI":"10.1249\/01.mss.0000174893.74326.11"},{"key":"2026091603501401000_13.2.e004312.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-022-01454-3"},{"key":"2026091603501401000_13.2.e004312.25","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.91.1.76"},{"key":"2026091603501401000_13.2.e004312.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2016.01.00833"},{"key":"2026091603501401000_13.2.e004312.27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40615-016-0335-8","article-title":"Racial\/Ethnic Disparities in Diabetes Quality of Care: the Role of Healthcare Access and Socioeconomic Status","volume":"5","author":"Canedo","year":"2018","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026091603501401000_13.2.e004312.28","article-title":"Social determinants of health among African Americans in a rural community in the Deep South: an ecological exploration","volume":"11","author":"Scott","year":"2011","journal-title":"Rural Remote Health"},{"key":"2026091603501401000_13.2.e004312.29","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1627"},{"key":"2026091603501401000_13.2.e004312.30","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1089\/dia.2021.0268","article-title":"Health Care Disparities in Use of Continuous Glucose Monitoring","volume":"23","author":"Isaacs","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"2026091603501401000_13.2.e004312.31","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/S0735-1097(25)02054-6","article-title":"Racial and ethnic differences in outcomes in patients with diabetic cardiomyopathy treated with an aldolase reductase inhibitor","volume":"85","author":"Lopez","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2026-004312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:50:33Z","timestamp":1789555833000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2026-004312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,7,31]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/openhrt-2026-004312"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2026-004312","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}